#1 Clinical Trials Search in Europe

Study on Acetylsalicylic Acid for Colorectal Cancer Patients with PI3K Pathway Mutations

3 1 1

What is this study about?

This clinical trial is focused on studying the effects of a treatment for patients with colorectal cancer, specifically those with certain genetic changes known as mutations in the PI3K signaling pathway. The treatment being tested is Acetylsalicylic Acid (ASA), commonly known as aspirin, which will be given in a dose of 160 mg once daily. The study aims to find out if this treatment can help delay the return of cancer in these patients compared to a placebo.

Participants in the study will have colon or rectal cancer at stages II or III, with specific genetic changes in their tumors, such as PIK3CA, PIK3R1, or PTEN. The study will last for three years, during which time patients will take the medication or placebo orally. The main goal is to see if the treatment can improve the time it takes for the cancer to come back after surgery.

The trial is designed to be a randomized, double-blind, placebo-controlled study, meaning neither the patients nor the researchers will know who is receiving the actual medication or the placebo. This approach helps ensure that the results are reliable and unbiased. The study will help determine if ASA can be an effective additional treatment for patients with these specific types of genetic changes in their cancer.

1 joining the study

Upon joining the study, the patient is randomly assigned to one of two groups: one receiving the active medication and the other receiving a placebo. This process is double-blind, meaning neither the patient nor the researchers know which group the patient is in.

2 medication administration

The patient takes one tablet daily. The active medication is acetylsalicylic acid (ASA), with a dosage of 160 mg. The placebo tablet looks the same as the active medication but does not contain the active substance.

The medication is taken orally, which means it is swallowed.

3 treatment duration

The treatment lasts for a total of three years. During this time, the patient continues to take the daily tablet as instructed.

4 monitoring and follow-up

Throughout the study, the patient’s health and response to the treatment are monitored. This includes regular check-ups and assessments to track any changes in the patient’s condition.

5 end of study

At the end of the three-year period, the patient’s participation in the study concludes. The primary goal is to determine if the treatment has improved the time to recurrence of cancer in patients with specific genetic mutations.

Who Can Join the Study?

  • The patient must have a tumor with somatic alterations in genes called PIK3CA, PIK3R1, or PTEN. Somatic alterations are changes in the genes that occur in the cells of the body, not inherited from parents.
  • The patient must have colon cancer at stage II-III or rectal cancer at stage I-III. These stages describe the size and spread of the cancer.
  • The patient must be between 18-80 years old, including both ages.
  • The patient must have had radical surgery, which means surgery aimed at removing all cancer, as confirmed by a surgeon and a pathologist.
  • The patient must have a Karnofsky performance status of 60% or higher. This is a scale that measures the patient’s ability to perform daily activities, with higher numbers indicating better ability.
  • The patient must have platelets of 100 x 109 / L or higher. Platelets are cells in the blood that help with clotting.
  • The patient must have had a clean colonoscopy or Computed Tomography (CT) colon within 3 months before or after surgery, but before joining the study. A colonoscopy is a test to look inside the colon, and a CT colon is a special scan of the colon.
  • The patient must be able to swallow tablets.
  • The patient must be able to understand and sign a written informed consent form, which means they agree to participate in the study after understanding what it involves.

Who Cannot Join the Study?

  • Patients who have a different type of cancer than colon or rectal cancer.
  • Patients whose cancer does not have specific changes in genes called PIK3CA, PIK3R1, or PTEN. These are genes that can affect how cells grow.
  • Patients who are not in the age range specified for the study.
  • Patients who are not able to take the study medication safely.
  • Patients who are pregnant or breastfeeding.
  • Patients who have other serious health conditions that might interfere with the study.
  • Patients who are unable to follow the study procedures or attend the required visits.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Jorvi Hospital Espoo Finland
Region Vaestmanland Vasteras Sweden

Other Sites

Site Name City Country Status
Danderyds Sjukhus AB Danderyd Sweden
Region Oestergoetland Linkoping Sweden
Region Oerebro Laen Orebro Sweden
Region Vaesterbotten Umea Sweden
St. Olavs Hospital HF Trondheim Norway
Region Dalarna Falun Sweden
Skaraborg Hospital-Vaestra Goetalandsregionen Skovde Sweden
Region Blekinge Karlskrona Sweden
Region Skane Lasarettet I Ystad Ystad Sweden
Region Vaesternorrland Sundsvall Sweden
Vrinnevisjukhuset I Norrkoeping Region Oestergoetland Norrkoping Sweden
Region Norrbotten Lulea Sweden
NU Hospital Group-Vaestra Goetalandsregionen Trollhattan Sweden
Region Skane Skanes Universitetssjukhus Lund Sweden
Regionshospitalet Viborg Viborg Denmark
Karolinska University Hospital Solna Sweden
Sankt Gorans Sjukhus Stockholm Sweden
Region Joenkoepings Laen Jönköping Sweden
Queen Silvia Childrens Hospital – Sahlgrenska University Hospital – Vaestra Goetalandsregionen Gothenburg Sweden
Region Midtjylland Randers Denmark
Soedersjukhuset AB Stockholm Sweden
Embev Sfkhmiimvmopp Hoopcsck Stockholm Sweden
Stylmnjug Hdb Scnqgguch urvkykxjrotyfgmsqwa Stavanger Norway
Asbqhlsn Uiihthlmvm Hbiqqtvq Lorenskog Norway
Uoibhnc Uvtmmtpojy Hqhnqier Uppsala Sweden
Hhlwazlr Ueejjxvkkw Cuufcew Habnfoho Helsinki Finland
Afrupk Uczpocydrc Hwdqyark Aarhus Denmark
Rxhhaa Vbavxkaja Karlstad Sweden

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Denmark Denmark
Not yet recruiting
01.04.2016
Finland Finland
Not yet recruiting
01.04.2016
Norway Norway
Not yet recruiting
01.04.2016
Sweden Sweden
Not yet recruiting
01.04.2016

Trial locations

Investigated drugs:

Acetylsalicylic Acid (ASA) is being studied to see if it can help prevent the return of colorectal cancer in patients who have specific genetic changes in their cancer cells. In this trial, patients take ASA once a day for three years to see if it can improve the time it takes for the cancer to come back after initial treatment.

Investigated diseases:

Colon and Rectal Cancer – This type of cancer originates in the colon or rectum, which are parts of the large intestine. It typically begins as small, noncancerous clumps of cells called polyps that form on the inside of the colon or rectum. Over time, some of these polyps can become cancerous. The disease is often classified by stages, with stage II-III indicating that the cancer has grown into or through the wall of the colon or rectum but has not spread to distant sites. Tumors with somatic alterations in genes like PIK3CA, PIK3R1, or PTEN may have specific characteristics that influence their behavior and progression. These genetic changes can affect how the cancer grows and responds to certain treatments.

Trial ID:
2024-513778-23-00
NCT ID:
NCT02647099
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.

    Recruiting

    3 1 1
    Investigated drugs:
    Belgium Czechia Denmark Finland France Germany +4

  • A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors

    Recruiting

    2 1 1
    Investigated drugs:
    Spain